GURUFOCUS.COM » STOCK LIST » USA » OTCPK » Melinta Therapeutics Inc (OTCPK:MLNTQ) » Definitions » Beneish M-Score
Switch to:

Melinta Therapeutics Beneish M-Score

: 0.00 (As of Today)
View and export this data going back to 2012. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Melinta Therapeutics's Beneish M-Score or its related term are showing as below:

During the past 10 years, the highest Beneish M-Score of Melinta Therapeutics was 0.00. The lowest was 0.00. And the median was 0.00.


Melinta Therapeutics Beneish M-Score Historical Data

The historical data trend for Melinta Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Melinta Therapeutics Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Beneish M-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.54 42,431.85 11.86 30,251.71 3.89

Melinta Therapeutics Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Beneish M-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 569.80 3.89 -0.57 -1.16 -2.81

Competitive Comparison

For the Biotechnology subindustry, Melinta Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Melinta Therapeutics Beneish M-Score Distribution

For the Biotechnology industry and Healthcare sector, Melinta Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Melinta Therapeutics's Beneish M-Score falls into.



Melinta Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Melinta Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.3896+0.528 * 0.8579+0.404 * 0.6148+0.892 * 1.249+0.115 * 1.1284
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.6393+4.679 * -0.1387-0.327 * 2.5778
=-4.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep19) TTM:Last Year (Sep18) TTM:
Total Receivables was $18.93 Mil.
Revenue was 15.87 + 15.955 + 14.084 + 35.489 = $81.40 Mil.
Gross Profit was 7.657 + 7.316 + 6.719 + 26.5 = $48.19 Mil.
Total Current Assets was $131.27 Mil.
Total Assets was $228.49 Mil.
Property, Plant and Equipment(Net PPE) was $5.50 Mil.
Depreciation, Depletion and Amortization(DDA) was $16.70 Mil.
Selling, General, & Admin. Expense(SGA) was $112.75 Mil.
Total Current Liabilities was $128.05 Mil.
Long-Term Debt & Capital Lease Obligation was $156.05 Mil.
Net Income was -213.382 + -36.18 + -26.532 + -44.12 = $-320.21 Mil.
Non Operating Income was -183.024 + 0.269 + 5.596 + -20.702 = $-197.86 Mil.
Cash Flow from Operations was -26.822 + -25.676 + -37.321 + -0.835 = $-90.65 Mil.
Total Receivables was $38.90 Mil.
Revenue was 34.078 + 12.022 + 14.841 + 4.231 = $65.17 Mil.
Gross Profit was 20.685 + 1.033 + 7.155 + 4.231 = $33.10 Mil.
Total Current Assets was $165.07 Mil.
Total Assets was $482.30 Mil.
Property, Plant and Equipment(Net PPE) was $2.31 Mil.
Depreciation, Depletion and Amortization(DDA) was $12.97 Mil.
Selling, General, & Admin. Expense(SGA) was $141.21 Mil.
Total Current Liabilities was $123.66 Mil.
Long-Term Debt & Capital Lease Obligation was $108.98 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(18.933 / 81.398) / (38.904 / 65.172)
=0.23259785 / 0.59694347
=0.3896

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(33.104 / 65.172) / (48.192 / 81.398)
=0.5079482 / 0.59205386
=0.8579

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (131.267 + 5.503) / 228.491) / (1 - (165.07 + 2.312) / 482.302)
=0.40142062 / 0.65295188
=0.6148

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=81.398 / 65.172
=1.249

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(12.97 / (12.97 + 2.312)) / (16.698 / (16.698 + 5.503))
=0.8487109 / 0.75212828
=1.1284

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(112.745 / 81.398) / (141.206 / 65.172)
=1.38510774 / 2.16666667
=0.6393

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((156.051 + 128.047) / 228.491) / ((108.976 + 123.659) / 482.302)
=1.24336626 / 0.48234301
=2.5778

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-320.214 - -197.861 - -90.654) / 228.491
=-0.1387

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Melinta Therapeutics has a M-score of -4.14 suggests that the company is unlikely to be a manipulator.


Melinta Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Melinta Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Melinta Therapeutics Business Description

Melinta Therapeutics logo
Traded in Other Exchanges
N/A
Address
44 Whippany Road, Morristown, NJ, USA, 07963
Melinta Therapeutics Inc is a clinical-stage biotechnology company that develops differentiated antibiotics for acute care and community settings. The company's goal is to develop treatments for bacterial infectious diseases, particularly respiratory tract infections and staphylococcal infections. The company is particularly focused on treating community-acquired bacterial pneumonia, as well as gonorrhea and other indications.
Executives
Johnson John director, officer: Chief Executive Officer DENDREON CORPORATION 1301 2ND AVENUE SEATTLE WA 98101
Koestler Thomas P director 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033
Zaccardelli David director 300 TRI STATE INTERNATIONAL SUITE 272 LINCOLNSHIRE IL 60069
Gill David N director C/O NXSTAGE MEDICAL INC. (NXTM) 439 SOUTH UNION STREET, 5TH FLOOR LAWRENCE MA 01843
Downey Bruce director
Kong Garheng director 712 COLLEGE AVENUE MENLO PARK CA 94025
Wechsler Daniel Mark director, officer: See Remarks 2150 ST. ELZEAR BLVD. WEST LAVAL A8 H7L 4A8
Temperato John officer: Chief Commercial Officer C/O MELINTA THERAPEUTICS,INC. 300 GEORGE STREET, SUITE 301 NEW HAVEN CT 06511
Goldstein Dov A Md director
Dougherty Michael R director C/O ADOLOR CORP 700 PENNSYLVANIA DR EXTON PA 19341
Neff P Sherrill director C/O RESOURCE AMERICA, INC. 1845 WALNUT STREET, 18TH FLOOR PHILADELPHIA PA 19103
Fernandes Prabhavathi director, officer: President and CEO 114 MILTON AVENUE CHAPEL HILL NC 27514
Intersouth Partners Vii L P 10 percent owner 406 BLACKWELL SUITE 200 DURHAM NC 27701
Intersouth Associates Vii, Llc 10 percent owner 406 BLACKWELL STREET SUITE 200 DURHAM NC 27701
Intersouth Associates Vi, Llc 10 percent owner 406 BLACKWELL STREET SUITE 200 DURHAM NC 27701
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)